Download TAG Mail 23 November 2016

TAG Mail 23 November 2016
The purpose of TAG Mail is to assist TAG members identify and share relevant information for their
professional practice. Members are encouraged to routinely forward TAG Mail to others who they
believe would benefit from this information such as colleagues in the same hospital department if they
are not already receiving TAG Mail.
TAG ACTIVITIES
** NSW TAG Life Saving Drugs Registers
- The Life Saving Drugs Register - Antivenoms 2016 will be uploaded to the website today. These
Antivenom and Antidote registers are used by NSW hospitals, hospitals of other jurisdictions, retrieval
services and Poisons Information Centres across Australia to provide 24-hour assistance in location of
antidote and antivenom stocks. As such, when NSW TAG has not received stock information from a
hospital, the hospital will be listed with a ‘NO DETAILS PROVIDED’ notation. Hospitals which do not
stock antidotes or antivenoms will also be identified. For facilities that have not yet responded please
provide details using the following link https://www.surveymonkey.com/r/antivenom2016
** Margaret Jordan is attending the Anticoagulant Medicines Working Party at the Clinical Excellence
Commission (CEC) on Friday 25 November. The NOAC guidelines are published on the CEC website
http://www.cec.health.nsw.gov.au/__data/assets/pdf_file/0007/326419/noac_guidelines.pdf
The working party is now developing guidance for the management of antithrombotic agents in the
perioperative period. For more information, please contact Margaret ([email protected])
TAG WEBSITE
**CIAP
- CIAP has disabled the following forms on the NSW TAG website:
http://www.ciap.health.nsw.gov.au/nswtag/about/contact.html
http://www.ciap.health.nsw.gov.au/nswtag/about/how-to-apply.html
Please contact NSW TAG via email [email protected] or by calling 02 8382 2852.
CONSULTATIONS
**TGA
- Consultation: Orphan drug program- 2015 consultation outcomes and 2016 orphan drug program
proposal. Closes Friday 25 November 2016.
http://www.tga.gov.au/consultation/consultation-orphan-drug-program
- Consultation: Software as a Medical Device (SaMD) Clinical evaluation. Closes 2 December 2016
http://www.tga.gov.au/consultation/consultation-software-medical-device-samd-clinical-evaluation
REPORTS AND PUBLICATIONS – AUSTRALIA
**AIHW
- Emergency department care 2015-16: Australian hospital statistics
http://www.aihw.gov.au/publication-detail/?id=60129557372
**NPS MedicineWise
- NPS Direct October 2016
http://www.nps.org.au/health-professionals/e-newsletters/nps-direct/2016/october
**NSW Health
- Neonatal – Jaundice Identification and Management in Neonates > 32 Weeks Gestation
http://www0.health.nsw.gov.au/policies/gl/2016/GL2016_027.html
**TGA
- Recall: Kaiser Pharmaceutical Traditional Chinese Medicine Products – potential for adverse events
relating to aristolochic acid(s).
http://www.tga.gov.au/alert/kaiser-pharmaceutical-traditional-chinese-medicine-products
- Registration of new prescription medicines:
--Ixazomib (NinlaroTM) for use in combination with lenalidomide and dexamethasone for the
treatment of multiple myeloma who have received at least one prior therapy.
--Alpha 1-proteinase inhibitor (Prolastin CTM) indicated to increase serum Alpha 1-PI levels in adults
with congenital deficiency of alpha-1 antitrypsin and with clinically significant emphysema
(FEV1<80%).
http://www.tga.gov.au/prescription-medicines-registration-new-chemical-entities-australia
- AusPAR added: Netupitant/Palonosetron (Akynezo TM) for the prevention of acute and delayed
nausea and vomiting associated with initial and repeat courses of highly emetogenic and of
moderately emetogenic cancer chemotherapy in adults.
http://www.tga.gov.au/auspar/auspar-netupitant-palonosetron-hydrochloride
- AusPAR added: Selexipag (UptraviTM) for patients with WHO functional class II, III or IV symptoms for
the treatment of idiopathic pulmonary arterial hypertension; heritable pulmonary arterial
hypertension; pulmonary arterial hypertension associated with connective tissue disease/congenital
heart disease with repaired shunts/ with drugs and toxins.
http://www.tga.gov.au/auspar/auspar-selexipag
- AusPAR added: Tenofovir disoproxil fumarate/emtricitabine (TruvadaTM) now also
indicated in combination with safer sex practices for pre-exposure prophylaxis (PrEP) to reduce risk of
sexually acquired HIV-1 in adults at high risk.
http://www.tga.gov.au/auspar/auspar-tenofovir-disoproxil-fumarate-emtricitabine
- AusPAR added: Secukinumab (CosentyxTM / ZafrezTM) for the treatment of adult patients with active
psoriatic arthritis when the response to previous disease-modifying anti rheumatic drug (DMARD)
therapy inadequate, and for the treatment of adult patients with active ankylosing spondylitis.
http://www.tga.gov.au/auspar/auspar-secukinumab-1
- Updates to the prescribing medicines in pregnancy database: Six newly registered medicines added
and 65 previously registered medicines added.
http://www.tga.gov.au/updates-prescribing-medicines-pregnancy-database
REPORTS AND PUBLICATIONS – INTERNATIONAL
**EMA
- EPAR added: Lenvatinib (KisplyxTM) for the treatment of adults with advanced renal cell carcinoma
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004224/human
_med_002021.jsp&mid=WC0b01ac058001d124
**ISMP
Is an indication-based prescribing system in our future?
http://www.ismp.org/newsletters/acutecare/showarticle.aspx?id=1153
**NICE
-Intrapartum care for healthy women and babies
https://www.nice.org.uk/guidance/cg190
MEDICATION SAFETY
**NSW Health
- Implantable cardiac defibrillator and cardiac resynchronization therapy defibrillator devices
http://www.health.nsw.gov.au/sabs/Documents/2016-sn-013.pdf
**MHRA
- Brimonidine gel (Mirvaso): risk of exacerbation of rosacea
https://www.gov.uk/drug-safety-update/brimonidine-gel-mirvaso-risk-of-exacerbation-of-rosacea
**NHS
Patient Safety Alert: Risk of severe harm and death due to withdrawing insulin from pen devices
https://improvement.nhs.uk/news-alerts/risk-severe-harm-and-death-withdrawing-insulin-pendevices/
PAPERS OF INTEREST
**AJHP
- ASHP Foundation Pharmacy Forecast 2017: Strategic Planning Advice for Pharmacy Departments in
Hospitals and Health Systems
http://www.ajhp.org/content/early/2016/11/18/sp170001?papetoc
- Meta-analysis of ascorbic acid for prevention of postoperative atrial fibrillation after cardiac surgery
http://www.ajhp.org/content/early/2016/11/15/ajhp160066
- Evaluation of a protocol to optimize duration of pneumonia therapy at hospital discharge
http://www.ajhp.org/content/early/2016/11/15/ajhp160011
- Precision medicine in oncology: New practice models and roles for oncology pharmacists
http://www.ajhp.org/content/73/23/1935.abstract?etoc
- Implementation of inpatient models of pharmacogenetics programs
http://www.ajhp.org/content/73/23/1944.abstract?etoc
-Integrating pharmacogenomics into electronic health records with clinical decision support
http://www.ajhp.org/content/73/23/1967.abstract?etoc
- Evidence and resources to implement pharmacogenetic knowledge for precision medicine
http://www.ajhp.org/content/73/23/1977.abstract?etoc
- Educational strategies to enable expansion of pharmacogenomics-based care
http://www.ajhp.org/content/73/23/1986.abstract?etoc
**Annals of Internal Medicine
- A Reporting Tool for Practice Guidelines in Health Care: The RIGHT Statement
http://annals.org/aim/article/2587367/reporting-tool-practice-guidelines-health-care-rightstatement
**BMJ
- Community acquired pneumonia incidence before and after proton pump inhibitor prescription:
population based study
http://www.bmj.com/content/355/bmj.i5813
- Management of mild hypertension in adults
http://www.bmj.com/content/355/bmj.i5719
** Canadian Medical Association Journal
- Association between statin use and ischemic stroke or major hemorrhage in patients taking
dabigatran for atrial fibrillation
http://www.cmaj.ca/content/early/2016/11/21/cmaj.160303
**Cochrane Library
- Drug therapies for reducing gastric acidity in people with cystic fibrosis
http://onlinelibrary.wiley.com/wol1/doi/10.1002/14651858.CD003424.pub4/full
- Steroid avoidance or withdrawal for kidney transplant recipients
http://onlinelibrary.wiley.com/wol1/doi/10.1002/14651858.CD005632.pub3/full
-Pharmacological interventions for pruritus in adult palliative care patients
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008320.pub3/abstract;jsessionid=264FF92C
44A674EED5B0CFD70375FEA4.f03t02
**JAMA
-Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients, The GLAGOV
Randomized Clinical Trial
http://jamanetwork.com/journals/jama/fullarticle/2584184
**JAMA Internal Medicine
- Association of 3 Different Antihypertensive Medications with Hip and Pelvic Fracture Risk in Older
Adults: Secondary Analysis of a Randomized Clinical Trial
http://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2587085
**Journal of Clinical Oncology
- Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients with Advanced Melanoma
http://ascopubs.org/doi/abs/10.1200/JCO.2015.66.1389
**MJA
- Antimicrobial use in Australian hospitals: how much and how appropriate?
https://www.mja.com.au/journal/2016/205/10/antimicrobial-use-australian-hospitals-how-muchand-how-appropriate
-Nocebo effects in practice: methotrexate myths and misconceptions
https://www.mja.com.au/journal/2016/205/10/nocebo-effects-practice-methotrexate-myths-andmisconceptions
**NEJM
- Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
http://www.nejm.org/doi/full/10.1056/NEJMoa1602773
- Palbociclib and Letrozole in Advanced Breast Cancer
http://www.nejm.org/doi/full/10.1056/NEJMoa1607303
**Paediatrics
- Intravenous versus Oral Antibiotics for Post-discharge Treatment of Complicated Pneumonia
http://pediatrics.aappublications.org/content/early/2016/11/15/peds.2016-1692
**The Lancet
-Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year
efficacy and safety results from the randomised EXXELERATE study
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)31651-8/fulltext
-Intratympanic methylprednisolone versus gentamicin in patients with unilateral Ménière's disease: a
randomised, double-blind, comparative effectiveness trial
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)31461-1/fulltext
UPCOMING EVENTS (new additions in bold)
**2nd Digital Hospital of the Future, ANZ 2016
‘Improving Patient Care Delivery and Monitoring with Digital Technology Innovations and
Transformation’ 7th-9th December 2016, InterContinental Sydney Australia
http://claridenglobal.com/conference/digitalhospital2016/?utm_campaign=L6285_Digital%20Hospita
l_AU_EDM%202_Buy&utm_medium=email&utm_source=Eloqua
**Australian Society for Antimicrobials
Adelaide. 23 - 25 February and 25 - 26 February 2017
Abstract Submission Deadline: Friday, 9 December 2016
www.antimicrobials2017.com
** 10th Pharmaceutical Care Network Europe (PCNE) Working Conference
‘Lead – Engage- Disseminate’
1 - 4 February 2017 in Bled, Slovenia.
http://www.pcne.org/conference/23/10th-pcne-working-conference-2017
**ISMP CHA Medication Safety Intensive, Sydney, March 9-10 2017. Early bird ends 31 October 2016
https://children.wcha.asn.au/ismp_medsafety
**CADTH Symposium, April 23, 2017 - April 25, 2017: Shaw Centre, Ottawa, Ontario
https://www.cadth.ca/events/2017-cadth-symposium
**2017 NSW Patient Experience Symposium, 1st-2nd May 2017 Bay 4, Australian Technology Park,
Eveleigh NSW
http://www.alignmentevents.com.au/sh_events/2017-nsw-patient-experience-symposium-call-forabstracts/#1473648903182-6aa8fa3c-649b
You are receiving this email because you or a workplace colleague has requested TAG Mail. NSW TAG
analyses uptake of TAG Mail (email openings and clicks on specific contents) in order to optimise the
TAG Mail service for our members and colleagues. By requesting TAG Mail, you are also agreeing to
have your data (email address, country of abode) captured. All information obtained is used in
accordance with NSW Health Privacy Policy. Please contact NSW TAG at [email protected] if
you have any questions regarding this.